KRMD Stock Intrinsic Value – KORU MEDICAL SYSTEMS Reports Earnings Results for FY2023 Q3

November 21, 2023

🌥️Earnings Overview

KORU MEDICAL SYSTEMS ($NASDAQ:KRMD) reported their FY2023 Q3 earnings results on November 8, 2023. The company had total revenue of USD 7.0 million, a decrease of 9.8% compared to the same quarter in the prior year. While their net income was USD -1.4 million, this was an improvement from the -1.2 million reported in Q3 of the previous year.

Price History

The news came with some mixed results as the stock opened at $2.4 but closed at $2.2, a decrease of 5.2% from the prior closing price of $2.3. This was in contrast to the market consensus which was expecting an increase. In addition to these decreases, KORU MEDICAL SYSTEMS reported a decrease in their operating expenses by 1%. Despite the earnings results, KORU MEDICAL SYSTEMS remains optimistic about their future.

They have announced plans to expand their product offerings and invest in research and development over the coming quarters. They also plan on continuing to focus on creating cost effective and innovative solutions to meet customer needs. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for KRMD. More…

    Total Revenues Net Income Net Margin
    28.68 -8.25 -28.6%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for KRMD. More…

    Operations Investing Financing
    -4.65 -0.83 -0.19
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for KRMD. More…

    Total Assets Total Liabilities Book Value Per Share
    35.35 7.92 0.6
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for KRMD are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    2.9% 37.4% -36.9%
    FCF Margin ROE ROA
    -19.1% -23.8% -18.7%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – KRMD Stock Intrinsic Value

    At GoodWhale, we have conducted a thorough analysis of the fundamentals of KORU MEDICAL SYSTEMS. Our proprietary Valuation Line indicates an intrinsic value of around $3.7 per share for KORU MEDICAL SYSTEMS. However, the current market price of KORU MEDICAL SYSTEMS stock is only $2.2, resulting in a 39.8% undervaluation of the stock. This presents a good opportunity for investors to buy at a discounted price and benefit from potential upside in the future. More…

  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Repro-Med Systems Inc. is a leading designer and manufacturer of specialty medical devices and pharmaceuticals. Its competitors are Merit Medical Systems Inc, Touchstone International Medical Science Co Ltd, and Medeon Biodesign Inc. All three companies are large, well-established firms with strong reputations in the medical device industry.

    – Merit Medical Systems Inc ($NASDAQ:MMSI)

    Medsite is a medical technology company that manufactures and markets medical devices and software. The company has a market capitalization of $3.33 billion and a return on equity of 5.86%. Medsite’s products are used by healthcare professionals worldwide to improve patient care and outcomes.

    – Touchstone International Medical Science Co Ltd ($SHSE:688013)

    The company’s market cap is 1.86B as of 2022 and its ROE is 3.8%. The company is engaged in the medical science field and is dedicated to providing innovative products and services to improve human health.

    – Medeon Biodesign Inc ($TPEX:6499)

    Medeon Biodesign Inc is a medical device company that designs, manufactures, and markets products for use in the fields of cardiology, orthopedics, and general surgery. The company has a market cap of 4.43B as of 2022 and a return on equity of -6.27%. Medeon Biodesign’s products are used in the treatment of conditions such as heart disease, arthritis, and cancer. The company’s products are sold through a network of distributors and retailers worldwide.


    KORU MEDICAL SYSTEMS reported their earnings results for FY2023 Q3, with total revenue of USD 7.0 million and a net income of USD -1.4 million. This resulted in a drop in stock price on the same day. Investors should consider this information carefully when making any decisions regarding KORU MEDICAL SYSTEMS. It is worth noting that the company has seen a decrease in total revenue which could affect its bottom line and future performance.

    Additionally, investors should look into factors such as market conditions, product performance, and competitive landscape to gain a better understanding of the company’s potential.

    Recent Posts

    Leave a Comment